Nikhil Prasad Fact checked by:Thailand Medical News Team Aug 14, 2026 49 minutes ago
A potential new eye-drop treatment for dry eye syndrome has shown encouraging results in laboratory and animal experiments, with researchers reporting improvements in inflammation-related eye damage and protection of important tear-film-supporting cells.
Experimental fenofibric acid eye drops reduced corneal swelling and improved recovery of protective goblet cells in a
rat model of dry eye
The experimental treatment uses fenofibric acid, or FFA, the active metabolite of fenofibrate, a medicine commonly used to control high cholesterol and triglycerides. Scientists are now investigating whether its anti-inflammatory properties could be redirected toward diseases affecting the eye.
Researchers Explore a Different Approach To Dry Eye
The researchers were from the Eye Hospital and School of Ophthalmology and Optometry at Wenzhou Medical University, China; Guizhou Provincial People’s Hospital, China; and the Department of Ophthalmology, Jacob’s Retina Center at Shiley Eye Institute, University of California San Diego, United States.
Dry eye is not simply a shortage of tears. Inflammation of the eye surface can damage the cornea and conjunctiva and reduce goblet cells, specialized cells that produce mucins needed to maintain a stable, protective tear film.
Fenofibric acid activates PPAR-alpha, a biological pathway associated with regulation of inflammation. The researchers therefore tested whether applying FFA directly as eye drops could control inflammatory damage.
Eye Drops Penetrated Important Eye Tissues
Laboratory testing showed that FFA dissolved far better in phosphate-buffered saline than ordinary saline, reaching a saturated concentration approximately 81 times higher. Experiments also confirmed that FFA could pass through the cornea, conjunctiva and sclera/choroid tissues.
The researchers subsequently tested a 500 micrograms-per-milliliter formulation, equivalent to 0.05 percent FFA. Twice-daily administration showed good ocular safety in rats, with no observed conjunctival congestion or corneal fluorescein staining during two weeks of safety testing.
Importantly, this Thailand
Medical News report highlights that after a single 500 micrograms-per-milliliter drop, FFA remained detectable in ocular tissues and blood for at least seven hours. Peak concentrations were highest in the aqueous humor, followed by the retina/choroid and vitreous.
Dry Eye Damage Improved
For the treatment experiment, researchers created dry-eye-like ocular surface damage in rats using benzalkonium chloride. Fifteen male rats were assigned to receive either FFA eye drops or saline twice daily for 28 days.
The most striking findings involved corneal swelling and conjunctival goblet cells. FFA-treated eyes showed significantly greater improvement in corneal edema than saline-treated eyes. The researchers also observed improvement in abnormal corneal blood-vessel growth.
Goblet cells provided anot
her important signal. Benzalkonium chloride reduced goblet-cell numbers by about 55 percent. Although both saline and FFA allowed some recovery after the damaging chemical was stopped, FFA produced significantly stronger recovery. Treated eyes had approximately 20 more goblet cells per square millimeter, representing an improvement of about 18 percent over saline.
Conclusions
The findings suggest that topical fenofibric acid could eventually provide a new strategy for controlling ocular surface inflammation while protecting goblet cells and helping damaged corneal tissue recover. However, these are preclinical findings from rats, not evidence that FFA eye drops are already safe or effective for human dry eye patients. Human clinical trials will be necessary before its therapeutic value can be established.
The study findings were published in the peer reviewed journal: Pharmaceutics.
https://www.mdpi.com/1999-4923/18/8/998
Read Also:
https://www.thailandmedical.news/articles/ophthalmology-(eye-diseases)
Share
Tweet
Share
